Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-02

AUTHORS

Daigo Yamamoto, Nobuaki Sato, Yoshiaki Rai, Yutaka Yamamoto, Mitsue Saito, Hiroji Iwata, Norikazu Masuda, Shoji Oura, Junichiro Watanabe, Satoshi Hattori, Yoshimasa Matsuura, Katsumasa Kuroi

ABSTRACT

PURPOSE: The randomized phase III JO21095 trial compared the efficacy and safety of low-dose capecitabine plus docetaxel combination therapy (XT) versus single-agent administration of docetaxel in anthracycline-pretreated HER2-negative metastatic breast cancer. METHODS: Patients were randomized to either low-dose XT (capecitabine 825 mg/m2 twice daily, days 1-14; docetaxel 60 mg/m2, day 1 every 3 weeks) or docetaxel (70 mg/m2, day 1 every 3 weeks). The primary objective was to demonstrate superior progression-free survival (PFS) with low-dose XT versus single-agent docetaxel. Overall survival (OS) and safety were secondary endpoints. RESULTS: In total, 162 patients were treated. Median PFS was 10.5 months with low-dose XT and 9.8 months with single-agent docetaxel (hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.40-0.97]; p = 0.03). The OS HR was 0.89 (95% CI 0.52-1.53; p = 0.68). Grade ≥3 treatment-related toxicities occurred in 74% of XT-treated patients and 76% of docetaxel-treated patients. The main differences in grade ≥3 treatment-related toxicities were hand-foot syndrome (7.3% of XT-treated patients vs 0% receiving docetaxel), fatigue/malaise (2.4 vs 10.0%), and peripheral edema (1.2 vs 7.5%). Dose modifications were required in 100% of low-dose XT and 49% of docetaxel patients. Toxicity-related treatment discontinuations occurred in 18 and 33%, respectively. CONCLUSION: The improved PFS with low-dose XT versus docetaxel alone is consistent with higher-dose XT phase III experience, but the safety profile was more favorable and manageable. More... »

PAGES

473-482

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-016-4075-6

DOI

http://dx.doi.org/10.1007/s10549-016-4075-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038909314

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28005247


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anthracyclines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retreatment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kansai Medical University", 
          "id": "https://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Surgery, Kansai Medical University Medical Center, 10-15 Fumizono cho, 570-8507, Moriguchi City, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Daigo", 
        "id": "sg:person.01114146464.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114146464.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Niigata Cancer Center Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416203.2", 
          "name": [
            "Department of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sato", 
        "givenName": "Nobuaki", 
        "id": "sg:person.013031030272.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013031030272.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rai", 
        "givenName": "Yoshiaki", 
        "id": "sg:person.01354262275.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354262275.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kumamoto University", 
          "id": "https://www.grid.ac/institutes/grid.274841.c", 
          "name": [
            "Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Yutaka", 
        "id": "sg:person.014073050404.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014073050404.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Juntendo University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411966.d", 
          "name": [
            "Department of Breast Surgical Oncology, Juntendo University Hospital, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saito", 
        "givenName": "Mitsue", 
        "id": "sg:person.01250120375.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250120375.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aichi Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwata", 
        "givenName": "Hiroji", 
        "id": "sg:person.013142720612.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013142720612.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Osaka National Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416803.8", 
          "name": [
            "Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masuda", 
        "givenName": "Norikazu", 
        "id": "sg:person.01335110475.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335110475.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wakayama Medical University", 
          "id": "https://www.grid.ac/institutes/grid.412857.d", 
          "name": [
            "Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oura", 
        "givenName": "Shoji", 
        "id": "sg:person.0613246516.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613246516.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shizuoka Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.415797.9", 
          "name": [
            "Department of Breast Oncology, Shizuoka Cancer Center, Shizuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "Junichiro", 
        "id": "sg:person.0607224004.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607224004.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kurume University", 
          "id": "https://www.grid.ac/institutes/grid.410781.b", 
          "name": [
            "Biostatistics Center, Kurume University, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hattori", 
        "givenName": "Satoshi", 
        "id": "sg:person.01324626411.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324626411.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.418587.7", 
          "name": [
            "Medical Affairs, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsuura", 
        "givenName": "Yoshimasa", 
        "id": "sg:person.016157330205.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016157330205.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tokyo Metropolitan Komagome Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415479.a", 
          "name": [
            "Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuroi", 
        "givenName": "Katsumasa", 
        "id": "sg:person.01170740213.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170740213.28"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2010.33.9101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007059596"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000329066", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009111613"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp498", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013665910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70546-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015669631"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021817259"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-0788-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027199206", 
          "https://doi.org/10.1007/s10549-010-0788-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-0788-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027199206", 
          "https://doi.org/10.1007/s10549-010-0788-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr256", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027799337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.6557", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029261491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.0982", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032315475"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq069", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036647457"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi253", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039198919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi253", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039198919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040646048"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2010-0278", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049400477"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clbc.2011.06.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052051084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.09.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/2530286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069975816"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02", 
    "datePublishedReg": "2017-02-01", 
    "description": "PURPOSE: The randomized phase III JO21095 trial compared the efficacy and safety of low-dose capecitabine plus docetaxel combination therapy (XT) versus single-agent administration of docetaxel in anthracycline-pretreated HER2-negative metastatic breast cancer.\nMETHODS: Patients were randomized to either low-dose XT (capecitabine 825\u00a0mg/m2 twice daily, days 1-14; docetaxel 60\u00a0mg/m2, day 1 every 3\u00a0weeks) or docetaxel (70\u00a0mg/m2, day 1 every 3\u00a0weeks). The primary objective was to demonstrate superior progression-free survival (PFS) with low-dose XT versus single-agent docetaxel. Overall survival (OS) and safety were secondary endpoints.\nRESULTS: In total, 162 patients were treated. Median PFS was 10.5\u00a0months with low-dose XT and 9.8\u00a0months with single-agent docetaxel (hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.40-0.97]; p\u00a0=\u00a00.03). The OS HR was 0.89 (95% CI 0.52-1.53; p\u00a0=\u00a00.68). Grade \u22653 treatment-related toxicities occurred in 74% of XT-treated patients and 76% of docetaxel-treated patients. The main differences in grade \u22653 treatment-related toxicities were hand-foot syndrome (7.3% of XT-treated patients vs 0% receiving docetaxel), fatigue/malaise (2.4 vs 10.0%), and peripheral edema (1.2 vs 7.5%). Dose modifications were required in 100% of low-dose XT and 49% of docetaxel patients. Toxicity-related treatment discontinuations occurred in 18 and 33%, respectively.\nCONCLUSION: The improved PFS with low-dose XT versus docetaxel alone is consistent with higher-dose XT phase III experience, but the safety profile was more favorable and manageable.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10549-016-4075-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "161"
      }
    ], 
    "name": "Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial", 
    "pagination": "473-482", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b958186b18b120f8e0bef87d7fc1815d15cfd91fee7c4faeec16feae4e005c35"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28005247"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-016-4075-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038909314"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-016-4075-6", 
      "https://app.dimensions.ai/details/publication/pub.1038909314"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113650_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10549-016-4075-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-016-4075-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-016-4075-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-016-4075-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-016-4075-6'


 

This table displays all metadata directly associated to this object as RDF triples.

291 TRIPLES      21 PREDICATES      61 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-016-4075-6 schema:about N04685cfd73fa4adeb785fd54a35a256c
2 N4a2963e4efc247ffa1f98c7468fa0247
3 N5218a67ebfb34077b66feefec954132d
4 N754aa8153f324f4491bc27d16011acd9
5 N85fa2d9b12e6413b9164bd41c0ba1736
6 N860e8197dc364ebe967f98eff55f8bb2
7 N897cc970e53f4b559c46100cae882880
8 N975681d327754808afffe3fbe4adea6e
9 Nb0d1a0bbc1914173a0406691a60744ee
10 Nb3e20215c21541228a3c476a97491c1c
11 Nc703309b13664a3387345999ba648bda
12 Nca34dc41e5834e37980294db6c8533dc
13 Ncc42cf8ffd88489d81554693633d0371
14 Nd317deb33a294d319027421f990bfa17
15 Nd62363e5758347c39adcac5987137a21
16 Ndcbd6f89ec5340e6a7af462993b92166
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N2fa5972f45ba4c7493b90b12cd4d4cb3
20 schema:citation sg:pub.10.1007/s10549-010-0788-0
21 https://doi.org/10.1016/j.clbc.2011.06.005
22 https://doi.org/10.1016/s1470-2045(13)70546-1
23 https://doi.org/10.1093/annonc/mdi253
24 https://doi.org/10.1093/annonc/mdl134
25 https://doi.org/10.1093/annonc/mdp498
26 https://doi.org/10.1093/annonc/mdq069
27 https://doi.org/10.1093/annonc/mdr256
28 https://doi.org/10.1159/000329066
29 https://doi.org/10.1200/jco.2002.09.002
30 https://doi.org/10.1200/jco.2007.12.6557
31 https://doi.org/10.1200/jco.2010.28.0982
32 https://doi.org/10.1200/jco.2010.33.9101
33 https://doi.org/10.1634/theoncologist.2010-0278
34 https://doi.org/10.2307/2530286
35 https://doi.org/10.3322/caac.21166
36 schema:datePublished 2017-02
37 schema:datePublishedReg 2017-02-01
38 schema:description PURPOSE: The randomized phase III JO21095 trial compared the efficacy and safety of low-dose capecitabine plus docetaxel combination therapy (XT) versus single-agent administration of docetaxel in anthracycline-pretreated HER2-negative metastatic breast cancer. METHODS: Patients were randomized to either low-dose XT (capecitabine 825 mg/m2 twice daily, days 1-14; docetaxel 60 mg/m2, day 1 every 3 weeks) or docetaxel (70 mg/m2, day 1 every 3 weeks). The primary objective was to demonstrate superior progression-free survival (PFS) with low-dose XT versus single-agent docetaxel. Overall survival (OS) and safety were secondary endpoints. RESULTS: In total, 162 patients were treated. Median PFS was 10.5 months with low-dose XT and 9.8 months with single-agent docetaxel (hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.40-0.97]; p = 0.03). The OS HR was 0.89 (95% CI 0.52-1.53; p = 0.68). Grade ≥3 treatment-related toxicities occurred in 74% of XT-treated patients and 76% of docetaxel-treated patients. The main differences in grade ≥3 treatment-related toxicities were hand-foot syndrome (7.3% of XT-treated patients vs 0% receiving docetaxel), fatigue/malaise (2.4 vs 10.0%), and peripheral edema (1.2 vs 7.5%). Dose modifications were required in 100% of low-dose XT and 49% of docetaxel patients. Toxicity-related treatment discontinuations occurred in 18 and 33%, respectively. CONCLUSION: The improved PFS with low-dose XT versus docetaxel alone is consistent with higher-dose XT phase III experience, but the safety profile was more favorable and manageable.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree false
42 schema:isPartOf N0ab68d2626534aa2a398d49383feae04
43 N2ef170af353f404785477acb63515187
44 sg:journal.1092777
45 schema:name Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
46 schema:pagination 473-482
47 schema:productId N60371c8b2af7406c8cad9e5376bc9913
48 Nad2c223044304af89745c4ced4f2ae2a
49 Nb5ac1c18a7684a8e9e5e93d0bdaf16ae
50 Nca65fe20245a4186b0d749fc6bbda4ce
51 Ne3e935a6ec4d4db8af69dbc4ae524cb6
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038909314
53 https://doi.org/10.1007/s10549-016-4075-6
54 schema:sdDatePublished 2019-04-11T10:31
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N2ce442999e2c4541ac9c76113346a06e
57 schema:url https://link.springer.com/10.1007%2Fs10549-016-4075-6
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N04685cfd73fa4adeb785fd54a35a256c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Docetaxel
63 rdf:type schema:DefinedTerm
64 N0ab68d2626534aa2a398d49383feae04 schema:issueNumber 3
65 rdf:type schema:PublicationIssue
66 N2ce442999e2c4541ac9c76113346a06e schema:name Springer Nature - SN SciGraph project
67 rdf:type schema:Organization
68 N2ef170af353f404785477acb63515187 schema:volumeNumber 161
69 rdf:type schema:PublicationVolume
70 N2fa5972f45ba4c7493b90b12cd4d4cb3 rdf:first sg:person.01114146464.53
71 rdf:rest N514726938d7e4fe58f6cf9fd9a195339
72 N3207f56891454c3d9c7932557153de62 rdf:first sg:person.014073050404.82
73 rdf:rest Na3269a698ef84d4d863c1029505e23e1
74 N37df10b8d8bf43e4b88081ac454f250c rdf:first sg:person.01324626411.61
75 rdf:rest N69700b8a44db4e3c9342b9f7ef75bb35
76 N4a2963e4efc247ffa1f98c7468fa0247 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Neoplasm Staging
78 rdf:type schema:DefinedTerm
79 N514726938d7e4fe58f6cf9fd9a195339 rdf:first sg:person.013031030272.26
80 rdf:rest Ncdbfda4ea0594ec8ab6a75fae682a545
81 N5218a67ebfb34077b66feefec954132d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Breast Neoplasms
83 rdf:type schema:DefinedTerm
84 N549f0d8840a44637b513e55ccffa8867 rdf:first sg:person.013142720612.73
85 rdf:rest Nbcdc258b1c7a482a8e1242cb697cd8d2
86 N60371c8b2af7406c8cad9e5376bc9913 schema:name dimensions_id
87 schema:value pub.1038909314
88 rdf:type schema:PropertyValue
89 N668223f1e2b84b5db4c3e6e217375a27 rdf:first sg:person.0613246516.13
90 rdf:rest Nebfc2f802e3c404bac32f1a7bbfcfe5d
91 N69700b8a44db4e3c9342b9f7ef75bb35 rdf:first sg:person.016157330205.32
92 rdf:rest Nb55f3070020840079649c8d003db4769
93 N754aa8153f324f4491bc27d16011acd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Retreatment
95 rdf:type schema:DefinedTerm
96 N85fa2d9b12e6413b9164bd41c0ba1736 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Aged
98 rdf:type schema:DefinedTerm
99 N860e8197dc364ebe967f98eff55f8bb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Taxoids
101 rdf:type schema:DefinedTerm
102 N897cc970e53f4b559c46100cae882880 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Quality of Life
104 rdf:type schema:DefinedTerm
105 N975681d327754808afffe3fbe4adea6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Female
107 rdf:type schema:DefinedTerm
108 Na3269a698ef84d4d863c1029505e23e1 rdf:first sg:person.01250120375.28
109 rdf:rest N549f0d8840a44637b513e55ccffa8867
110 Nad2c223044304af89745c4ced4f2ae2a schema:name doi
111 schema:value 10.1007/s10549-016-4075-6
112 rdf:type schema:PropertyValue
113 Nb0d1a0bbc1914173a0406691a60744ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Capecitabine
115 rdf:type schema:DefinedTerm
116 Nb3e20215c21541228a3c476a97491c1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Middle Aged
118 rdf:type schema:DefinedTerm
119 Nb55f3070020840079649c8d003db4769 rdf:first sg:person.01170740213.28
120 rdf:rest rdf:nil
121 Nb5ac1c18a7684a8e9e5e93d0bdaf16ae schema:name pubmed_id
122 schema:value 28005247
123 rdf:type schema:PropertyValue
124 Nbcdc258b1c7a482a8e1242cb697cd8d2 rdf:first sg:person.01335110475.17
125 rdf:rest N668223f1e2b84b5db4c3e6e217375a27
126 Nc703309b13664a3387345999ba648bda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Antineoplastic Combined Chemotherapy Protocols
128 rdf:type schema:DefinedTerm
129 Nca34dc41e5834e37980294db6c8533dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Anthracyclines
131 rdf:type schema:DefinedTerm
132 Nca65fe20245a4186b0d749fc6bbda4ce schema:name nlm_unique_id
133 schema:value 8111104
134 rdf:type schema:PropertyValue
135 Ncc42cf8ffd88489d81554693633d0371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Treatment Outcome
137 rdf:type schema:DefinedTerm
138 Ncdbfda4ea0594ec8ab6a75fae682a545 rdf:first sg:person.01354262275.36
139 rdf:rest N3207f56891454c3d9c7932557153de62
140 Nd317deb33a294d319027421f990bfa17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Humans
142 rdf:type schema:DefinedTerm
143 Nd62363e5758347c39adcac5987137a21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Survival Analysis
145 rdf:type schema:DefinedTerm
146 Ndcbd6f89ec5340e6a7af462993b92166 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Adult
148 rdf:type schema:DefinedTerm
149 Ne3e935a6ec4d4db8af69dbc4ae524cb6 schema:name readcube_id
150 schema:value b958186b18b120f8e0bef87d7fc1815d15cfd91fee7c4faeec16feae4e005c35
151 rdf:type schema:PropertyValue
152 Nebfc2f802e3c404bac32f1a7bbfcfe5d rdf:first sg:person.0607224004.36
153 rdf:rest N37df10b8d8bf43e4b88081ac454f250c
154 Nf3caa37847384f65873e1b869948abbf schema:name Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan
155 rdf:type schema:Organization
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
160 schema:name Oncology and Carcinogenesis
161 rdf:type schema:DefinedTerm
162 sg:journal.1092777 schema:issn 0167-6806
163 1573-7217
164 schema:name Breast Cancer Research and Treatment
165 rdf:type schema:Periodical
166 sg:person.01114146464.53 schema:affiliation https://www.grid.ac/institutes/grid.410783.9
167 schema:familyName Yamamoto
168 schema:givenName Daigo
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114146464.53
170 rdf:type schema:Person
171 sg:person.01170740213.28 schema:affiliation https://www.grid.ac/institutes/grid.415479.a
172 schema:familyName Kuroi
173 schema:givenName Katsumasa
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170740213.28
175 rdf:type schema:Person
176 sg:person.01250120375.28 schema:affiliation https://www.grid.ac/institutes/grid.411966.d
177 schema:familyName Saito
178 schema:givenName Mitsue
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250120375.28
180 rdf:type schema:Person
181 sg:person.013031030272.26 schema:affiliation https://www.grid.ac/institutes/grid.416203.2
182 schema:familyName Sato
183 schema:givenName Nobuaki
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013031030272.26
185 rdf:type schema:Person
186 sg:person.013142720612.73 schema:affiliation https://www.grid.ac/institutes/grid.410800.d
187 schema:familyName Iwata
188 schema:givenName Hiroji
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013142720612.73
190 rdf:type schema:Person
191 sg:person.01324626411.61 schema:affiliation https://www.grid.ac/institutes/grid.410781.b
192 schema:familyName Hattori
193 schema:givenName Satoshi
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324626411.61
195 rdf:type schema:Person
196 sg:person.01335110475.17 schema:affiliation https://www.grid.ac/institutes/grid.416803.8
197 schema:familyName Masuda
198 schema:givenName Norikazu
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335110475.17
200 rdf:type schema:Person
201 sg:person.01354262275.36 schema:affiliation Nf3caa37847384f65873e1b869948abbf
202 schema:familyName Rai
203 schema:givenName Yoshiaki
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354262275.36
205 rdf:type schema:Person
206 sg:person.014073050404.82 schema:affiliation https://www.grid.ac/institutes/grid.274841.c
207 schema:familyName Yamamoto
208 schema:givenName Yutaka
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014073050404.82
210 rdf:type schema:Person
211 sg:person.016157330205.32 schema:affiliation https://www.grid.ac/institutes/grid.418587.7
212 schema:familyName Matsuura
213 schema:givenName Yoshimasa
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016157330205.32
215 rdf:type schema:Person
216 sg:person.0607224004.36 schema:affiliation https://www.grid.ac/institutes/grid.415797.9
217 schema:familyName Watanabe
218 schema:givenName Junichiro
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607224004.36
220 rdf:type schema:Person
221 sg:person.0613246516.13 schema:affiliation https://www.grid.ac/institutes/grid.412857.d
222 schema:familyName Oura
223 schema:givenName Shoji
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613246516.13
225 rdf:type schema:Person
226 sg:pub.10.1007/s10549-010-0788-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027199206
227 https://doi.org/10.1007/s10549-010-0788-0
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1016/j.clbc.2011.06.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052051084
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1016/s1470-2045(13)70546-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015669631
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1093/annonc/mdi253 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039198919
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1093/annonc/mdl134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040646048
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1093/annonc/mdp498 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013665910
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1093/annonc/mdq069 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036647457
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1093/annonc/mdr256 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027799337
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1159/000329066 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009111613
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1200/jco.2002.09.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203115
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1200/jco.2007.12.6557 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029261491
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1200/jco.2010.28.0982 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032315475
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1200/jco.2010.33.9101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007059596
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1634/theoncologist.2010-0278 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049400477
254 rdf:type schema:CreativeWork
255 https://doi.org/10.2307/2530286 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069975816
256 rdf:type schema:CreativeWork
257 https://doi.org/10.3322/caac.21166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021817259
258 rdf:type schema:CreativeWork
259 https://www.grid.ac/institutes/grid.274841.c schema:alternateName Kumamoto University
260 schema:name Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.410781.b schema:alternateName Kurume University
263 schema:name Biostatistics Center, Kurume University, Fukuoka, Japan
264 rdf:type schema:Organization
265 https://www.grid.ac/institutes/grid.410783.9 schema:alternateName Kansai Medical University
266 schema:name Department of Surgery, Kansai Medical University Medical Center, 10-15 Fumizono cho, 570-8507, Moriguchi City, Osaka, Japan
267 rdf:type schema:Organization
268 https://www.grid.ac/institutes/grid.410800.d schema:alternateName Aichi Cancer Center
269 schema:name Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
270 rdf:type schema:Organization
271 https://www.grid.ac/institutes/grid.411966.d schema:alternateName Juntendo University Hospital
272 schema:name Department of Breast Surgical Oncology, Juntendo University Hospital, Tokyo, Japan
273 rdf:type schema:Organization
274 https://www.grid.ac/institutes/grid.412857.d schema:alternateName Wakayama Medical University
275 schema:name Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
276 rdf:type schema:Organization
277 https://www.grid.ac/institutes/grid.415479.a schema:alternateName Tokyo Metropolitan Komagome Hospital
278 schema:name Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
279 rdf:type schema:Organization
280 https://www.grid.ac/institutes/grid.415797.9 schema:alternateName Shizuoka Cancer Center
281 schema:name Department of Breast Oncology, Shizuoka Cancer Center, Shizuoka, Japan
282 rdf:type schema:Organization
283 https://www.grid.ac/institutes/grid.416203.2 schema:alternateName Niigata Cancer Center Hospital
284 schema:name Department of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan
285 rdf:type schema:Organization
286 https://www.grid.ac/institutes/grid.416803.8 schema:alternateName Osaka National Hospital
287 schema:name Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
288 rdf:type schema:Organization
289 https://www.grid.ac/institutes/grid.418587.7 schema:alternateName Roche (Japan)
290 schema:name Medical Affairs, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
291 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...